This study aimed to evaluate the geographic distribution of Chimeric Antigen Receptor (CAR) T-cell therapy clinical trials for childhood cancer and assess their alignment with global health needs. Using a quantitative approach, we analyzed data on 317 clinical trials from the WHO’s Global Observatory on Health Research and Development (2007–2022) alongside global health metrics, stratified by WHO region. Our results show a profound geographic imbalance: 56.7 % of trials occurred in the Western Pacific and 27.7 % in the Americas, while regions like Africa, the Eastern Mediterranean, and South-East Asia hosted almost none. Academic institutions were the primary sponsors (69.2 %). Correlational analysis revealed no statistically significant link between trial frequency and childhood cancer mortality rates. The only significant correlation found was between the number of trials and alcohol-related deaths in children aged 5–14 (r² = 0.67; p = 0.04). These findings indicate a stark misalignment between scientific research and the regions with the greatest pediatric oncology burden, highlighting significant scientific inequity. We conclude that structural barriers and misaligned funding prevent vulnerable populations from accessing these transformative therapies, necessitating a strategic shift in global policy to ensure equitable research distribution.
No hay comentarios:
Publicar un comentario